1 Short Title: VEE complex, MADV and EEEV

3		Venezuelan equine encephalitis complex, Madariaga and Eastern equine
4	e	ncephalitis viruses genome detection in human and mosquito populations
5		
6	J	ean-Paul Carrera ^{1,2,3,4#,} Dimelza Araúz ³ , Alejandra Rojas ⁵ , Fátima Cardozo ⁵ , Victoria
7	Stit	ttleburg ⁶ , Ingra Morales Claro ^{7,9} , Josefrancisco Galue ^{3,4} , Carlos Lezcano-Coba ^{3,4} , Filipe
8	Romer	o Rebello Moreira ^{8,9} , Luis Felipe-Rivera ^{3,4} , Maria Chen-Germán ³ , Brechla Moreno ³ , Zeuz
9	Capita	m-Barrios ^{3,4,10} , Sandra López-Vérges ³ , Juan Miguel Pascale ¹¹ , Ester C. Sabino ⁷ , Anayansi
10	Vald	errama ^{4,12,} Kathryn A. Hanley ¹³ , Christl A. Donnelly ^{2,9,14} , Nikos Vasilakis ^{+15, 16,17,18,19,20,}
11		Nuno R. Faria ^{+1,7,9,} Jesse J. Waggoner ^{+6,21,#}
12		
13	1.	Department of Biology, University of Oxford, Oxford, United Kingdom
14	2.	Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford,
15		Oxford, United Kingdom
16	3.	Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of
17		Health Studies, Panama City, Panama
18	4.	Viral Emerging Disease Dynamics group, Gorgas Memorial Institute of Health Studies,
19		Panama City, Panama
20	5.	Universidad Nacional de Asunción, Instituto de Investigaciones en Ciencias de la Salud,
21		Departamento de Producción, Paraguay
22	6.	Emory University, Department of Medicine, Division of Infectious Diseases, Atlanta,
23		Georgia, USA

24	7. Instituto de Medicina Tropical, Faculdade de Medicina da Universidade de São Paulo,
25	São Paulo, Brazil
26	8. Departamento de Genética, Universidade Federal do Rio de Janeiro, Brazil
27	9. MRC Centre for Global Infectious Disease Analysis (MRC-GIDA), Department of
28	Infectious Disease Epidemiology, Imperial College London, London United Kingdom
29	10. Departamento de Microbiología y Parasitología, Facultad de Ciencias Naturales, Exactas
30	y Tecnología, Universidad de Panamá, Ciudad de Panamá, Panamá
31	11. Clinical of Tropical Diseases and Research Unit, Gorgas Memorial Institute of Health
32	Studies, Panama City, Panama
33	12. Department of Medical Entomology, Gorgas Memorial Institute of Health Studies,
34	Panama City, Panama
35	13. Department of Biology, New Mexico State University, Las Cruces, New Mexico, USA
36	14. Department of Statistics, University of Oxford, Oxford, United Kingdom
37	15. Department of Pathology, The University of Texas Medical Branch, Galveston, Texas,
38	USA
39	16. Department of Preventive Medicine and Population Health, The University of Texas
40	Medical Branch, Galveston, Texas, USA.
41	17. Center for Biodefense and Emerging Infectious Diseases, The University of Texas
42	Medical Branch, Galveston, Texas, USA.
43	18. Center for Vector-Borne and Zoonotic Diseases, The University of Texas Medical
44	Branch, Galveston, Texas, USA.
45	19. Center for Tropical Diseases, The University of Texas Medical Branch, Galveston,
46	Texas, USA.

47	20. Institute for Human Infection and Immunity, The University of Texas Medical Branch,
48	Galveston, Texas, USA.
49	21. Rollins School of Public Health, Department of Global Health, Atlanta, Georgia, USA
50	
51	#Address correspondence to: Jean-Paul Carrera, Peter Medawar Building for Pathogen Research,
52	Oxford, UK, OX1 3SY. Email: jean.carrera@biology.ox.ac.uk; jpcarrera@gorgas.gob.pa or
53	Jesse J. Waggoner, 1760 Haygood Drive NE, Room E-169, Bay E-1, Atlanta, GA, USA, 30322.
54	Email: jjwaggo@emory.edu; Telephone: +1 (404) 712-2360.
55	
56	+joint senior authors
57	
58	Word Count: Abstract, 231; Manuscript, 4509
59	Inserts: Tables 4, Figure 4
60	

61 Abstract

62 Eastern equine encephalitis virus (EEEV), Madariaga virus (MADV) and Venezuelan equine 63 encephalitis virus complex (VEEV) are New World mosquito-borne alphaviruses and cause severe neurological disease in human and equine hosts. However, their detection during the acute 64 65 phase is complicated by non-specific clinical manifestations and lack of available diagnostic 66 tools. To develop and clinically evaluate rRT-PCRs for VEEV complex, MADV and EEEV, 67 primers and probes were designed from publicly available whole-genome sequences. The rRT-68 PCRs were validated using 15 retrospective serum samples from febrile patients collected during 69 the 2015 and 2017 alphavirus outbreaks in Panama. In addition, the protocol was validated with

70	150 mosquito pools from 2015, and with 118 samples from prospective disease surveillance from
71	2021 and 2022. The rRT-PCRs detected VEEV complex RNA in 10 samples (66.7%) from the
72	2015 and 2017 outbreaks, and in one of these ten samples, both VEEV complex and MADV
73	RNAs were detected. Additionally, VEEV complex RNA was detected in 5 suspected dengue
74	from prospective disease surveillance. The rRT-PCR assays detected VEEV complex RNA in 3
75	from Culex (Melanoconion) vomerifer pools, 2 of which yielded VEEV isolates. Untargeted
76	sequencing and phylogenetic analysis identified VEEV ID subtype in
77	seven VEEV complex RNA positive sample. The VEEV complex, MADV and EEEV rRT-
78	PCRs provide accurate detection while yielding significant benefits over currently available
79	molecular methods. Our results suggest that 11.9% of suspected dengue cases in Panama are
80	VEEV infections.
81	
82	Keywords: Venezuelan equine encephalitis, Madariaga virus, Easter equine encephalitis virus,
83	alphavirus, rRT-PCR.
84	
85	Introduction
86	New World alphaviruses (Togaviridae, genus Alphavirus) comprise a diverse group of mosquito-
87	borne viruses that can cause severe disease in humans, including the Venezuelan equine
88	encephalitis virus complex (VEEV complex), Madariaga virus (MADV), and eastern equine
89	encephalitis virus (EEEV)(1). These have single-stranded 11.7kb RNA genomes that encode four

- 90 non-structural proteins (nsP1 to nsP4) and five structural proteins (capsid, E1, E2, E3 and 6K) (1,
- 91 2). VEEV complex, MADV and EEEV persist in sylvatic-enzootic cycles throughout the

92 Americas and are transmitted to humans by *Aedes spp.*, *Psorophora spp.* and *Culex spp.*

93 mosquitoes (2, 3).

24	
95	Serologic and molecular evidence of VEEV complex infections have been identified throughout
96	tropical regions of Central and South America, suggesting VEEV complex infections may be
97	relatively common but remain largely underdiagnosed(2). There is a high genetic variability
98	within the VEEV complex, with at least 14 different viral subtypes identified to date (2). VEEV
99	complex subtypes have been associated with large epizootic outbreaks involving equids and
100	humans (VEEV subtypes IAB and IC)(1, 2). Although most infections in humans are
101	asymptomatic or subclinical, patients may develop acute febrile illness with headache, myalgias,
102	arthralgias, nausea, and vomiting (4, 5), which may progress to severe disease including
103	encephalitis and the development of long-term neurologic sequelae(5, 6).
104	
105	MADV, previously classified as South American EEEV, is an emerging virus that was first
106	associated with large outbreaks in 2010 in the Darién province of Panamá (5), where VEEV
107	subtype ID has also been detected(7). Before the 2010 outbreak in Panama, MADV was mostly
108	associated with equine disease and only a few human infections had been detected in Trinidad
109	and Tobago and Brazil(8, 9). This contrasts with the epidemiological profile of the North
110	American EEEV, which is associated with severe and fatal human cases(3). Diagnostic tools are
111	not widely available for MADV, and its prevalence outside of the Darién province in Panama
112	remains poorly characterized(10). Geographic expansion of the Panamanian MADV strain into
113	Northeast Brazil and Haiti has been reported recently, highlighting the potential of MADV to
114	invade new areas (11, 12).

Accurate detection of VEEV complex, MADV and EEEV infections in the acute phase is 115 116 complicated by their non-specific clinical manifestations and lack of widely available diagnostic 117 tools. Antigen-based methods are currently unavailable, and although serology can confirm the 118 diagnosis, this requires paired acute and convalescent samples (1, 5). Current molecular tests 119 lack optimal performance characteristics necessary for routine diagnostic testing (13–19). 120 Molecular assay designs have been complicated by the genetic variability of the VEEV complex 121 viruses(2). VEEV complex infections are often misdiagnosed as dengue virus, due to 122 overlapping clinical symptoms during the acute phase (2), and the recent classification of MADV 123 as a separate virus species and human pathogen further complicates the clinical diagnosis of 124 both(3). Common molecular tests for the VEEV complex employ pan-alphavirus primers to 125 amplify a region of 400-500 nucleotides region of the genome with subsequent identification of 126 the viral complex or species by sequencing or nested polymerase chain reaction (PCR)(5, 13, 14, 127 16, 18–20). Such methods are laborious and increase opportunities for laboratory contamination. 128 In addition, pan-alphavirus primers and conventional reverse transcription-polymerase chain 129 reaction (RT-PCR) chemistry may be less sensitive than real-time RT-PCR (rRT-PCR). 130 Moreover, few rRT-PCR methods have been reported in the literature to date to detect and 131 differentiate VEEV complex and MADV (21).

132

The primary objective of the current study was to design sensitive rRT-PCRs diagnosis assay for the VEEV complex and MADV. As a secondary objective, a duplex MADV/EEEV rRT-PCR was developed to differentiate these two pathogens. The two assays, for VEEV complex and MADV/EEEV detection, were evaluated in a set of clinical samples from an alphavirus outbreak in Panamá and prospective disease surveillance. Finally, we characterized viral species, subtype

138	and genotype fro	m selected rRT-PC	CR, positive sam	ples from l	humans and mo	squitoes c	collected

- during the 2015 and 2022 alphavirus outbreaks in Panama using metagenomic sequencing
- 140 approach.
- 141

142 Materials and Methods

143 **Ethics statement**

- 144 The use of human samples used for protocol validation was approved by the Panamanian
- 145 Ministry of Health (protocol number 2077), Gorgas's Institutional Review Board (IRB)
- 146 (protocol: 335/CBI/ICGES/21), Emory University IRB (IRB00097089), and the Ethics
- 147 Committee of the Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de
- 148 Asunción (P06/2017). Prospective disease surveillance was approved by the Gorgas's IRB
- 149 (protocol:073/CBI/ICGES/21).
- 150

151 Data availability

152 All the data used for human and mosquito validation are contained within the manuscript.

153 Accessions numbers of newly derived genomes are XXX. Accessions numbers and strains

154 information of sequences used for primer design are shown in Supplementary Appendix.

155

156 VEEV complex, EEEV and MADV rRT-PCR design

157 Separate alignments were prepared for the VEEV complex, EEEV and MADV using all publicly

- available complete genome sequences from the NCBI GenBank (22) and aligned with MegAlign
- 159 software (DNASTAR, Madison, WI). The VEEV complex alignment included all complete
- 160 genomes from the following viruses: Cabassou, Everglades, Mosso das Pedras, Mucambo,

161	Pixuna, Rio Negro, Tonate, and VEEV subtypes (IAB, IC, ID, and IE). The VEEV complex
162	alignments were compiled in 2016 (n=121 sequences); a similar alignment for MADV was
163	compiled in 2019 (n=32). Primers and probes were designed with Primer3 software
164	(primer3.ut.ee) such that each oligonucleotide contained ≤ 1 degenerate base and matched $\geq 95\%$
165	of available sequences for a given virus. In silico primer/probe specificity was checked by
166	aligning sequences in BLAST (blast.ncbi.nlm.nih.gov) against (i) all available sequences and (ii)
167	only alphavirus sequences while excluding the VEEV complex or MADV, respectively. Due to
168	the similarity between MADV primers and EEEV sequences, all available EEEV complete
169	genome sequences (n=441) were aligned and separate MADV and EEEV probes were designed
170	for an rRT-PCR duplex assay. Alignments for each virus were repeated with all sequences
171	available in September 2021 to confirm primer and probe sequences in contemporary strains.
172	
172 173	rRT-PCR assay performance and optimization
	rRT-PCR assay performance and optimization rRT-PCRs were performed in 25µL reactions using the SuperScript III Platinum One-Step
173	
173 174	rRT-PCRs were performed in 25µL reactions using the SuperScript III Platinum One-Step
173 174 175	rRT-PCRs were performed in 25µL reactions using the SuperScript III Platinum One-Step Quantitative RT-PCR Kit (Thermo Fisher, Waltham, MA) with 5µL of the nucleic acid template.
173 174 175 176	rRT-PCRs were performed in 25µL reactions using the SuperScript III Platinum One-Step Quantitative RT-PCR Kit (Thermo Fisher, Waltham, MA) with 5µL of the nucleic acid template. The analytical evaluation was performed on a Rotor-Gene Q instrument (Qiagen, Germantown,
173 174 175 176 177	rRT-PCRs were performed in 25µL reactions using the SuperScript III Platinum One-Step Quantitative RT-PCR Kit (Thermo Fisher, Waltham, MA) with 5µL of the nucleic acid template. The analytical evaluation was performed on a Rotor-Gene Q instrument (Qiagen, Germantown, MD), and the validation with serum and mosquito pool samples was performed on an ABI7500
173 174 175 176 177 178	rRT-PCRs were performed in 25µL reactions using the SuperScript III Platinum One-Step Quantitative RT-PCR Kit (Thermo Fisher, Waltham, MA) with 5µL of the nucleic acid template. The analytical evaluation was performed on a Rotor-Gene Q instrument (Qiagen, Germantown, MD), and the validation with serum and mosquito pool samples was performed on an ABI7500 (Thermo Fisher). Cycling conditions were consistent with previous laboratory protocols: 52 °C ×
173 174 175 176 177 178 179	rRT-PCRs were performed in 25µL reactions using the SuperScript III Platinum One-Step Quantitative RT-PCR Kit (Thermo Fisher, Waltham, MA) with 5µL of the nucleic acid template. The analytical evaluation was performed on a Rotor-Gene Q instrument (Qiagen, Germantown, MD), and the validation with serum and mosquito pool samples was performed on an ABI7500 (Thermo Fisher). Cycling conditions were consistent with previous laboratory protocols: 52 °C × 15 min, 94 °C × 2 min, and 45 cycles of 94 °C × 15 s, 55 °C × 40 s (acquired in all channels),

183	threshold (Ct) values, with preserved specificity. Primer and probe concentrations in the final
184	reaction were then adjusted between 100nM and 400nM to optimize assay sensitivity.
185	Primers were obtained from Integrated DNA Technologies (IDT, Coralville, Iowa); probes were
186	obtained from Biosearch Technologies (Hoddesdon, United Kingdom). VEEV subtype IC and
187	EEEV genomic RNAs were purchased from Vircell Microbiologists (Granada, Spain).
188	Quantified ssDNA containing the assay target region (IDT, Coralville, Iowa) was used for all
189	viruses to quantify analytical performance. For ssDNA synthesis, target region sequences were
190	selected from specific strains of VEE subtype IAB (Accession number KC344505.2) and
191	subtype IV (Pixuna virus, Accession number NC_038673.1), MADV (Accession numbers
192	MH359233.1 and KJ469626.1), and EEEV (Accession number KX029319.1).
193	
194	Analytical evaluation
195	The linear range of the assay was determined by testing synthesized targets from each reference
196	strain in quadruplicate at 8.0, 6.0, 4.0, 2.0, and 1.0 \log_{10} copies/µL. The linear range was defined
197	as the range of concentrations at which 1) all replicates were detected and 2) the linear regression

198 of Ct values (y, dependent variable) versus \log_{10} copies/ μ L (x, independent variable) generated

199 an $R^2 \ge 0.99$. For the VEEV complex, the lower limit 95% detection (95% LLOD) was

200 determined by testing 10 replicates of 2-fold serial dilutions from 200 to 25 copies/µl. For

201 MADV and EEEV, 95% LLOD was calculated directly from the linear range. Assay exclusivity

202 was evaluated by testing genomic RNA from the following viruses (strain in parentheses, if

203 designated): Rift Valley fever (h85/09); Zika (ZIJV; MR766); dengue virus serotype 1 (DENV1,

Hawwai 1944), DENV2 (NGC), DENV3 (Sleman/78), and DENV4 (H241); chikungunya virus

205 (CHIKVR80422); Mayaro virus (MAYV; ARV 0565, INHRR 11a-10); yellow fever virus

206	(YFV; 17D and Asibi strains); West Nile virus (WNV; NAL); St. Louis encephalitis virus
207	(SLEV; GML 902612, CorAn 9275); tick-borne encephalitis virus (TBEV; Japanese encephalitis
208	virus (JEV); Semliki Forest virus (SFV); Ross River virus (RRV); Getah virus (GETV); Barmah
209	Forest virus (BFV); and Una virus (UNAV) (5). Specificity was also evaluated by testing 56
210	serum samples from locations without known transmission of VEEV or MADV. These included
211	8 samples collected from patients in Georgia, USA, without known travel history, and 48
212	samples from individuals with an acute febrile illness in Asunción, Paraguay. The latter samples
213	have been described in detail elsewhere (23). Total nucleic acids were extracted from $200\mu L$ of
214	serum on an EMAG instrument (BioMérieux, Durham, NC), eluted in 50μ L and run in the
215	VEEV complex and MADV/EEEV rRT-PCRs.
216	
217	Statistics
218	Linear regression fitting and linear range calculations, including R^2 of the best-fit line were
219	performed in Excel (Microsoft, Redmond, WA). Concentrations and replicates in the linear range
220	study that did not yield Ct values were not included in the linear regression analysis. Probit
221	analyses were performed using MedCalc, v20.013 (MedCalc Software, Belgium).
222	
223	Protocol validation with acute human samples
224	Acute human samples used in the protocol validation were collected in communities of Darien,
225	the eastern most province in Panama, during three alphavirus outbreaks in 2015, 2017. Cases
226	identified in 2015 and 2017 were detected in the communities of Metetí, Cemaco, Tucutí,

227 Yaviza, Nicanor, La Palma and El Real de Santa María (Figure 1A). The Darien province

borders Colombia and encompasses the Darien Gap, and the Darien National Park, a UNESCOdesignated World Heritage Site(24).

230

231 Patient recruitment in 2015 and 2017

232 Febrile patients were identified during an enhanced surveillance program by our outbreak

response team using house-by-house visits during the 2015 and 2017 outbreaks. Blood samples

were drawn from patients that met the case definition during the outbreak investigation. The case

235 definition of a suspected case included fever and headache, while a probable case was defined as

a suspected case plus somnolence, lethargy, or convulsions. Blood samples were centrifuged in

the field, and serum was stored in liquid nitrogen for transportation to the Gorgas Memorial

238 Institute of Health Studies in Panama City.

239

240 **Prospective acute disease surveillance in 2021 and 2022**

In 2021 an effort for surveillance of emerging pathogens was established in Panama as part of
 the USA-National Institute of Allergy and Infectious Diseases (NIAID), Centers for Research in
 Emerging Infectious Diseases Network initiative. The Coordinating Research on Emerging

Arboviral Threats Encompassing the Neotropics (CREATE-NEO) in Panama undertakes acute

febrile surveillance across ten Health Centers in Panama and Darien Provinces (Figure 1 B)

246 (https://www.utmb.edu/createneo/home/create-neo-home). Cases, with malaria, human

247 immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis (HCV), and >5 and <75 years

248 old, presenting with no more than 7 days with rash, and at least one of the following symptoms:

249 fever, myalgia, arthralgia, periarticular edema, and conjunctivitis were recruited, evaluated and

250 interviewed, to obtain clinical, and demographics characteristics and ethic consent at each health

center.

252

253 Laboratory testing for acute disease surveillance

254 Acute samples (0-5 days) were first screened against DENV, CHIKV and ZIKV virus using rRT-

255 PCR as described previously (25), followed by testing with the newly designed MADV/VEEV

256 rRT-PCR.

257

258 Mosquito collection

259 Mosquito collections were performed in a forested section of 100 x 100 meters within El Real de 260 Santa María (Figure 1 A). Acute VEEV cases were identified during the 2015 outbreak response 261 in El Real de Santa María. Mosquito collections were undertaken with CDC light traps and 262 performed over a period of 12 hours, from 6:00 pm to 6:00 am at a height of 1.5 m above ground 263 level. Traps (BioQuip Products, Rancho Dominguez, CA) were baited with octanol and CO_2 for 264 the encephalitis vector survey. The following day, mosquitoes were collected in the field and 265 transported to the base camp where they were anesthetized, identified to the species level using 266 taxonomic keys (26), and placed in cryovials for storage in liquid nitrogen. Mosquitos were 267 grouped at the species level and a maximum of 20 individuals were used to produce mosquito 268 pools for rRT-PCR, serology, and isolation.

269

270 Alphavirus serology of clinical samples

271 All human serum samples were tested in duplicate for IgM antibodies to MADV and VEEV

antigen using an enzyme-linked immunosorbent assay (ELISA) and confirmed by a plaque-

273	reduction neutralization test (PRNT). For the ELISA, sucrose-acetone antigens were prepared
274	from MADV- (prepared by Dr. Robert Shope at the Yale Arbovirus Research Unit in August
275	1989) and VEEV- (strain TC-83) infected mouse brain. For the PRNT, we used chimeric Sindbis
276	virus SINV/MADV (derived from Brazilian MADV strain BeAn436087 and shown to be an
277	accurate surrogate for MADV in these assays (27) and TC83, an attenuated vaccine strain of
278	VEEV closely related to subtype ID strains that circulate in Panama (7). The neutralizing
279	antibody titer was determined as the reciprocal of the highest dilution that reduced plaque count
280	by 80% (PRNT ₈₀).
281	
282	Viral isolation from mosquito pools
283	Mosquito pool homogenates were prepared with $20 - 50$ mosquitoes in 2 mL of minimum
284	essential medium supplemented with penicillin and streptomycin, and 20% fetal bovine serum,
285	homogenized using a Tissue Lyser (Qiagen, Hidden, Germany), and centrifuged at 12000 rpm
286	for 10 mins. A total of 200 μ L of serum or mosquito homogenate was inoculated in each of two
287	12.5-cm ² flasks of Vero cells. Samples were passed twice and monitored for cytopathic effect

289

288

(CPE).

290 Generic alphavirus RT-PCR for human and mosquito samples

Viral RNA was extracted from human sera and mosquito pool homogenates using QIAamp RNA viral extraction kit (Qiagen, Valencia, CA). Viral RNA from mosquitoes was also extracted using the Macherey-Nagel extraction kit (Düren, Germany). Sera and mosquito homogenates were tested in 25µL reactions for alphaviruses using a universal alphavirus RT-PCR, as previously described (19).

296 Viral metagenomic sequencing

297 To confirm virus species, subtype and genotype, we sequenced seven selected VEEV complex 298 rRT-PCR positive mosquito and human samples from 2015 and 2022 using SMART-9N 299 metagenomic sequencing ad previously described (28). In brief, viral RNA was treated with 300 TURBO DNase (Thermo Fisher Scientific, USA) and concentrated with Zymo RNA clean & 301 concentrator-5 (Zymo Research, USA) following protocol instructions. cDNA synthesis and 302 PCR was performed as described (28). Fifty ng of the quantified PCR products were pooled 303 using EXP-NBD104 (1-12) and EXP-NBD114 (13-24) Native Barcoding Kits (ONT, UK). 304 Sequencing libraries were generated using the SQK-LSK109 kit (ONT, UK) and loaded onto 305 FLO-MIN106 flow cells on the GridION device (ONT, UK). Sequencing base-calling and 306 demultiplexing was performed by MinKNOW with the standard 48-hour run script (ONT, UK). 307 Demultiplexed FASTQ files were aligned and mapped to the VEEV reference genome (GenBank 308 accession no. NC 001449.1) using minimap2 version 2.28. (29) and converted to sorted BAM 309 file using SaMtool(30). NanoStat version 1.1.2.4,(31) and Tablet (32) were used to compute 310 genomic statistics. Variants were detected with medaka_variants and consensus sequences were 311 built with marging_medaka_consensus (ONT, UK). Genomic regions with <20x coverage were 312 masked.

313

314 **VEEV Phylogenetic analysis**

All available VEEV genome sequences, in GenBank, representing all antigenic complex were selected to construct the alignment, duplicated sequences, partial sequences and overlapping sequences were removed. Finally, the novel complete or near complete VEEV genome sequences (n=7) were aligned with 132 representative VEEV genomes retrieved from NCBI

319 GenBank using MAFFT version 7 (33). Selection of the best-fitting nucleotide substitution 320 model and maximum likelihood phylogenetic reconstruction were performed with IQ-Tree 321 v2.2.0.3(34). Statistical robustness of the tree topology was assessed with 1,000 ultrafast 322 bootstrap replicates.

323

324 **Results**

325 **rRT-PCR analytical evaluation**

326 Primers and probes for the VEE complex singleplex and MADV/EEEV duplex rRT-PCRs are

327 shown in Table 1 along with the optimized final reaction concentrations. The linear range for

each assay extended from 2.0 to 8.0 \log_{10} copies/ μ L (Figure 2A-D). For the VEEV complex

329 assay, the linear range was evaluated with ssDNA for subtypes IAB and IV and RNA from

subtype IC (2.0 to 5.0 \log_{10} copies/ μ L; Figure 1A-B). The 95% LLODs, expressed in copies/ μ L,

331 were: VEEV subtype IAB, 120; VEE subtype IV, 110; MADV, 19; EEEV, 19. Assay exclusivity

332 was evaluated by testing genomic RNA from VEEV subtype IC, EEEV, and a set of arboviruses,

including flavi-, bunya-, and alphaviruses on a single run of the VEEV complex and

334 MADV/EEEV rRT-PCRs. VEEV complex and EEEV only yielded signals in the respective

assays for these viruses. None of the other tested viruses generated signal in either assay. In

addition, none of the 56 serum samples from Georgia, USA, or Asunción, Paraguay, tested

337 positive in either assay.

338

339 Validation with clinical samples

A total of 15 febrile patients from 2015 and 2017 alphavirus outbreaks that met the suspected or
 probable case definition were used to validate the new molecular assays. Previously, a total of

342	eleven (11/15) acute sera samples collected during the in 2015 and 2017 alphavirus outbreaks
343	had tested positive using a generic alphavirus RT-PCR and were confirmed later by sequencing
344	as VEEV-ID infections (17). In 2021, a second round of generic alphavirus RT-PCR using the
345	same set of primers was run on these 15 stored samples, and all of them tested negative. Notably,
346	using the newly designed rRT-PCR, we were able to detect 10 VEEV complex RNA positive
347	samples (Ct range: $27 - 38$), including two samples that had tested negative at the initial
348	screening in 2017 (Table 2). Three of the VEEV complex rRT-PCR-positive samples were also
349	anti-VEEV IgG and IgM positive, with only 0, 2, and 3 days since the onset of symptoms,
350	respectively (Table 2). One sample was rRT-PCR positive for both VEEV and MADV viruses.
351	
352	Prospective disease surveillance
353	A total of 118 febrile patients were recruited from November 16, 2021, to December 1, 2022. Of
354	these 84 (71.2%) were acute patients with onset of symptoms ranging from 0-5 days. A total of
355	42 patients (50.0 %) were DENV1 positive. We detected VEEV RNA (Ct range: 15-20) in five
356	patients (11.9%; 95% CI: $4.0 - 25.6$) with suspected dengue infection, one of which was from a
357	fatal case in 2022. Details and results of disease surveillance are presented in Figure 3.
358	
359	Viral detection in mosquito pools
360	A total of 1307 mosquitoes belonging to 35 species and 12 genera were collected in the
361	community of El Real de Santa Maria, Panama, during a period of five days in 2015 (table 3).
362	The most abundant mosquito species was Coquilletidia venezualensis (37.5%, n=490 of 1307)
363	and Culex Melanoconion vomerifer (34,4%, n=450 of 1307). Mosquito species, number of
364	individuals and pools are shown in Table 3. Of 150 mosquito pools, 3 Cx. (Mel.) vomerifer

mosquito pools tested positive for VEEV by rRT-PCR (Ct range:26-30). Two of these rRT-PCR
positive pools also yielded viral isolates.

367

368 VEEV Subtype identification

369 Three mosquito pools and 4 human samples (including one from a fatal case in 2022), that tested

370 positive with the new VEEV complex rRT-PCR were sequenced using a virus untargeted

371 approach (<u>https://wellcomeopenresearch.org/articles/6-241</u>). Twenty-fold genome coverage

372 ranged from 45% to 100% (Table 4). Percentage of genome identity with VEEV reference strain

373 ranged from 87.7% to 90.0% (Table 4), while identity with the Panamanian VEEV ID subtype

prototype strain 3880 ranged from 96 to 97% (Table 4). Maximum likelihood phylogenetic

analysis indicated that the new viral genomes cluster together with historical Panamanian VEEV

376 ID subtype strains within the Panama/Peru genotype (bootstrap statistical support =100; Figure

4). Percentage of genome identity with VEEV reference strain ranged from 45% to 100% (Table

378 4).

379

380 **Discussion**

381 The VEEV complex, MADV and EEEV viruses have been detected throughout the Americas

and may account for a significant proportion of non-dengue acute febrile illness (2, 3, 5, 9).

383 Although several assays have been developed for the molecular detection of VEEV subtypes and

384 VEEV complex (14–20), many are laborious and time-consuming based in multiple PCR rounds

385 or posterior genome sequencing that can be only implemented in laboratories with appropriate

facilities (14–20). Co-circulation and the potential for co-infection with these viruses further

387 complicates their detection, particularly when they present similar clinical presentations and

388	there is a lack of available and convenient methods for detection of VEEV complex viruses and
389	MADV (19). For example, VEEV subtype ID and MADV have both been identified in Panamá,
390	and co-circulation of VEEV and MADV was detected in the Darién province of Panamá along
391	the Colombian border (5–7). Typically, cases are often detected during the neurological phase of
392	the disease (5, 35). At this stage, the virus has been cleared from the serum and diagnosis relies
393	mostly on serological testing. Because alphaviruses can induce an IgM response that lasts up to 2
394	to 3 months, the detection of anti-VEEV or anti-MADV IgM alone could yield a misdiagnosis if

395

seroconversion is not observed (5, 35).

396 We developed new accurate VEEV complex singleplex and MADV/EEEV duplex rRT-PCRs for 397 the detection of viral RNA and real-time differentiation of clinical and mosquito samples. Using 398 these assays, we detected VEEV ID subtype and MADV in samples that had tested negative with 399 a reference RT-PCR (19). We were also able to identify an individual with a VEEV ID subtype -400 MADV co-infection, highlighting another advantage of our VEEV complex and MADV/EEEV 401 rRT-PCRs over previous methods. Co-infection cases are epidemiologically significant and may 402 have clinical relevance if associated with more severe disease (5). Our newly developed rRT-403 PCR assays can be rapidly incorporated into diagnostic algorithms in endemic regions. We show 404 that the currently developed rRT-PCR allowed us to detect VEEV ID subtype RNA in samples 405 collected from patients at least within the first 5 days of symptoms, whereas alphavirus IgM and 406 IgG antibody responses usually develop >5-7 days post symptom onset (36). Interestingly, three 407 patients with detectable VEEV complex RNA were also VEEV IgM and IgG-reactive, 408 suggesting that VEEV re-infections are possible, a finding with potential implications for 409 alphavirus vaccine development.

410 Our newly developed rRT-PCR allows the detection of the recently identified VEEV ID subtype 411 in acute infections. Our results of prospective disease surveillance in Panama indicate that 11.9% 412 of suspected dengue cases are VEEV ID subtype infections and provide evidence for overlapping 413 alphavirus circulation with other endemic arboviral infections such as dengue. Moreover, our 414 findings support previous evidence suggesting that VEEV complex infections represent 10 % of 415 the dengue burden in Latin American endemic countries(2). VEEV complex infections are 416 clinically undistinguished from endemic infections such as dengue (2), thus the VEEV complex 417 burden may be underestimated in dengue endemic regions. 418 VEEV ID subtype RNA was detected in three mosquito pools from the Cx. (Mel.) vomerifer 419 species trapped during the 2015 outbreak in El Real de Santamaria, Panama. Mosquitoes, from 420 the Cx. (Mel.) vomerifer have been previously incriminated as a vector for VEEV ID subtype in 421 Panama (2). Two of these mosquito pools yielded viral isolates. None of the original pan-422 alphavirus convectional RT-PCRs were able to detect viral RNA in the mosquito pools. This 423 suggests that our newly designed rRT-PCR has an increased sensitivity to detect VEEV complex 424 RNA in mosquito vectors. No MADV nor EEEV infections were detected in mosquitoes by 425 either pan-alpha, rRT-PCR or isolation methods. The same pattern of lack of MADV isolation or 426 detection in mosquitoes was observed during previous outbreak investigations undertaken by our 427 group in Panama (37, 38). Interestingly, low MADV frequency of isolation was also observed 428 during extensive mosquito investigations undertaken during the 1940-60s in Panama by the 429 Gorgas Memorial Laboratory; in these occasions MADV was only isolated twice from Cx. (Mel.) 430 taeniopus in 1964 and 1973, respectively (39, 40). The low frequency of MADV detection or 431 isolation in Panama contrast with features observed in the endemic region of Iquitos, Peru, where 432 active circulation of MADV in the enzootic vector *Culex (Mel.) pedroi* is frequently detected(9,

41). Taken together, the early reports along with recent evidence suggest that mosquito vectors

433

434 in Panama may be infected with MADV at a lower frequency when compared with VEEV ID 435 subtype and even MADV in other endemic regions. The reasons for this variation in MADV and 436 VEEV ID subtype frequency of isolation or detection from mosquitoes collected in Panama 437 remain unclear and may include variation in vector competence or viral heterologous 438 competition or even enhanced VEEV ID subtype transmission by insect specific virus as has 439 been shown with dengue and Zika viruses (42). 440 Only a small number of human and mosquito samples were available to validate the assays. 441 However, prospective disease surveillance allowed us to obtain additional samples to further 442 validate our new assays. While previously developed methods relied on the validation of assays 443 using plasmids, viral isolates, or a few human sera samples (13–21), our assay validation with 444 human sera, mosquitos, and post-mortem tissue samples is more realistic and typical in reference 445 laboratories. Moreover, our approach failed to detect two samples that had previously tested 446 positive back in 2015 using standard alphavirus generic primers (19). Vina-Rodriguez et al., 447 reported an rRT-PCR that was designed from an alignment of 33 VEEV sequences (21). 448 Development of this assay did not include other species that comprise the VEEV complex, and 449 clinical samples were not available for evaluation (21). Our assays were designed using a greater 450 number of complete genome sequences with confirmation *in silico* that the primers and probes 451 match contemporary alignments. Interestingly, a second round of the generic alphavirus RT-PCR 452 undertaken in 2017 with the same primers have also failed to reamplify the former positives. 453 Viral RNA degradation over time is a likely explanation of these false negative samples(43). 454 Untargeted metagenomic sequencing of complete and near-complete genome sequences 455 confirmed that the VEEV ID subtype was detected using the VEEV complex primers; this

456 subtype has been detected in central and eastern Panama regions (7). Further VEEV ID subtype 457 evolutionary analyses are currently being undertaken to investigate host or vector adaptations. 458 Taken together, these data demonstrate the potential of molecular and genomic approaches to 459 improve the detection of VEE complex, MADV and EEEV acute infections, even in long-time 460 storage samples. 461 Additional prospective testing is warranted to fully characterize the assays' clinical and 462 surveillance performance. An additional limitation of this study is that the design requires two 463 separate assays for three viruses as the optimal design targets for the VEEV complex and MADV 464 overlap in a highly conserved region. However, the two rRT-PCRs can be performed together on 465 a single run, however, which improves lab workflow, and the VEEV complex assay can be 466 multiplexed with rRT-PCRs for other neurotropic arboviruses such as West Nile and St. Louis 467 encephalitis viruses without a loss in performance (manuscript in preparation). 468 In conclusion, we describe new sensitive and specific VEEV complex, MADV and EEEV rRT-469 PCRs that provide significant benefits over available molecular methods, allowing us to detect 470 VEEV-MADV co-infections and VEEV human infection in samples that were negative with 471 other techniques. Early acute samples that were negative with other techniques. Early acute 472 samples (\leq 3 days since onset of symptoms), with coincidental VEEV specific antibodies and 473 VEEV viral RNA suggest that VEEV re-infections are possible. In addition, our newly 474 developed method allowed us to detect VEEV active viral circulation in mosquitoes collected 475 during an alphavirus outbreak response. The implementation of then assays in regions of 476 endemicity may improve the identification and characterization of these neurotropic 477 alphaviruses.

4	7	9

480

481 Acknowledgements

- 482 We thank Xacdiel Rodriguez, Yelissa Rios, Yaneth Pittí, Oriel Lezcano and Eddier Rivera and
- 483 Mileika Santos for technical support with sample processing and mosquito classification and
- 484 Alberto Cumbrera for the map construction. We also thank Leyda Abrego for providing reagents
- 485 for the rRT-PCR and Milena Gomez, Thais M. Coletti, Esmenia Rocha, Geovana Maria Pererira,
- 486 Erika R. Manuli for technical support with metagenomic sequencing
- 487

488 **Funding Sources**

- 489 JPC is funded by the Clarendon Scholarship from University of Oxford and Lincoln-Kingsgate
- 490 Scholarship from Lincoln College, University of Oxford (grant number
- 491 SFF1920_CB2_MPLS_1293647). This work was supported by SENACYT, through the grants
- 492 number FID-16-201 and FID-2021-96 grant to JPC; the National Institute of Allergy and
- 493 Infectious Diseases, National Institutes of Health (grant K08AI110528 to JJW) and the National
- 494 Institute of Allergy and Infectious Diseases, National Institutes of Health (grant K08AI110528 to
- 495 JJW) and Centers for Research in Emerging Infectious Diseases (CREID) Coordinating
- 496 **R**esearch on Emerging Arboviral Threats Encompassing the Neotropics (CREATE-NEO)
- 497 1U01AI151807 grant awarded to NV/KAH by the National Institutes of Health (NIH); and by
- 498 the Medical Research Council São Paulo Research Foundation CADDE partnership award
- 499 (MR/S0195/1 and FAPESP18/14389 0 to NRF) (https://caddecentre.org). CAD was supported
- 500 by the NIHR HPRU in Emerging and Zoonotic Infections, a partnership between PHE,

- 501 University of Oxford, University of Liverpool and Liverpool School of Tropical Medicine (grant
- 502 no. NIHR200907).

503 **References**

504 1. Navarro JC, Carrera JP, Liria J, Auguste AJ, Weaver SC. 2017. Alphaviruses in Latin 505 America and the introduction of chikungunya virusHuman Virology in Latin America: 506 From Biology to Control. 507 Aguilar P v., Estrada-Franco JG, Navarro-Lopez R, Ferro C, Haddow AD, Weaver SC. 2. 508 2011. Endemic Venezuelan equine encephalitis in the Americas: Hidden under the dengue 509 umbrella. Future Virol https://doi.org/10.2217/fvl.11.50. 510 3. Arrigo NC, Adams AP, Weaver SC. 2010. Evolutionary Patterns of Eastern Equine 511 Encephalitis Virus in North versus South America Suggest Ecological Differences and 512 Taxonomic Revision. J Virol https://doi.org/10.1128/jvi.01586-09. 513 Forshey BM, Guevara C, Laguna-Torres VA, Cespedes M, Vargas J, Gianella A, Vallejo 4. 514 E, Madrid C, Aguavo N, Gotuzzo E, Suarez V, Morales AM, Beingolea L, Reves N, Perez 515 J, Negrete M, Rocha C, Morrison AC, Russell KL, Blair PJ, Olson JG, Kochel TJ. 2010. 516 Arboviral etiologies of acute febrile illnesses in western south America, 2000-2007. PLoS 517 Negl Trop Dis 4. 518 Carrera J-P, Forrester N, Wang E, Vittor AY, Haddow AD, López-Vergès S, Abadía I, 5. 519 Castaño E, Sosa N, Báez C, Estripeaut D, Díaz Y, Beltrán D, Cisneros J, Cedeño HG, 520 Travassos da Rosa AP, Hernandez H, Martínez-Torres AO, Tesh RB, Weaver SC. 2013. 521 Eastern Equine Encephalitis in Latin America. New England Journal of Medicine 522 https://doi.org/10.1056/nejmoa1212628. 523 Carrera JP, Pittí Y, Molares-Martínez JC, Casal E, Pereyra-Elias R, Saenz L, Guerrero I, 6. 524 Galué J, Rodriguez-Alvarez F, Jackman C, Pascale JM, Armien B, Weaver SC, Donnelly 525 CA, Vittor AY. 2020. Clinical and serological findings of madariaga and venezuelan

526		equine encephalitis viral infections: A follow-up study 5 years after an outbreak in
527		Panama. Open Forum Infect Dis https://doi.org/10.1093/ofid/ofaa359.
528	7.	Quiroz E, Aguilar P v., Cisneros J, Tesh RB, Weaver SC. 2009. Venezuelan equine
529		encephalitis in Panama: Fatal endemic disease and genetic diversity of etiologic viral
530		strains. PLoS Negl Trop Dis https://doi.org/10.1371/journal.pntd.0000472.
531	8.	Corniou B, Ardoin P, Bartholomew C, Ince W, Massiah V. 1972. First isolation of a South
532		American strain of Eastern Equine virus from a case of encephalitis in Trinidad. Trop
533		Geogr Med 24.
534	9.	Aguilar P v., Robich RM, Turell MJ, O'Guinn ML, Klein TA, Huaman A, Guevara C,
535		Rios Z, Tesh RB, Watts DM, Olson J, Weaver SC. 2007. Endemic eastern equine
536		encephalitis in the Amazon region of Peru. American Journal of Tropical Medicine and
537		Hygiene https://doi.org/10.4269/ajtmh.2007.76.293.
538	10.	Vittor AY, Armien B, Gonzalez P, Carrera J-P, Dominguez C, Valderrama A, Glass GE,
539		Beltran D, Cisneros J, Wang E, Castillo A, Moreno B, Weaver SC. 2016. Epidemiology of
540		Emergent Madariaga Encephalitis in a Region with Endemic Venezuelan Equine
541		Encephalitis: Initial Host Studies and Human Cross-Sectional Study in Darien, Panama.
542		PLoS Negl Trop Dis 10.
543	11.	Gil LHVG, Magalhaes T, Santos BSAS, Oliveira L v., Oliveira-Filho EF, Cunha JLR,
544		Fraiha ALS, Rocha BMM, Longo BC, Ecco R, Faria GC, Furtini R, Drumond SRM,
545		Maranhão RPA, Lobato ZIP, Guedes MIMC, Teixeira RBC, Costa EA. 2021. Active
546		circulation of madariaga virus, a member of the eastern equine encephalitis virus complex,
547		in northeast brazil. Pathogens 10.

- 548 12. Lednicky JA, White SK, Mavian CN, el Badry MA, Telisma T, Salemi M, OKech BA,
- 549 Beau De Rochars VM, Morris JG. 2019. Emergence of Madariaga virus as a cause of
- acute febrile illness in children, Haiti, 2015-2016. PLoS Negl Trop Dis
- 551 https://doi.org/10.1371/journal.pntd.0006972.
- 552 13. Pfeffer M, Proebster B, Kinney RM, Kaaden OR. 1997. Genus-specific detection of
- alphaviruses by a semi-nested reverse transcription-polymerase chain reaction. American
- 554 Journal of Tropical Medicine and Hygiene 57.
- 555 14. Brightwell G, Brown JM, Coates DM. 1998. Genetic targets for the detection and

identification of Venezuelan equine encephalitis viruses. Arch Virol 143.

- 557 15. Romeiro MF, de Souza WM, Tolardo AL, Vieira LC, Henriques DA, de Araujo J,
- 558 Siqueira CEH, Colombo TE, Aquino VH, da Fonseca BAL, de Morais Bronzoni RV,
- 559 Nogueira ML, Durigon EL, Figueiredo LTM. 2016. A real-time RT-PCR for rapid

560 detection and quantification of mosquito-borne alphaviruses. Arch Virol 161.

- 16. Linssen B, Kinney RM, Aguilar P, Russell KL, Watts DM, Kaaden OR, Pfeffer M. 2000.
- 562 Development of reverse transcription-PCR assays specific for detection of equine
- 563 encephalitis viruses. J Clin Microbiol 38.
- 564 17. Wang E, Paessler S, Aguilar P v., Carrara AS, Ni K, Greene IP, Weaver SC. 2006.
- Reverse transcription-PCR-enzyme-linked immunosorbent assay for rapid detection and
 differentiation of alphavirus infections. J Clin Microbiol 44.
- 567 18. Pisano MB, Seco MPS, Ré VE, Farías AA, Contigiani MS, Tenorio A. 2012. Specific
- 568 detection of all members of the Venezuelan Equine Encephalitis complex: Development
- of a RT-Nested PCR. J Virol Methods 186.

570	19.	Sánchez-Seco MP	Rosario D. C	Duiroz E.	Guzmán G.	Tenorio A.	2001. A	generic nested-

- 571 RT-PCR followed by sequencing for detection and identification of members of the
- alphavirus genus. J Virol Methods https://doi.org/10.1016/S0166-0934(01)00306-8.
- 573 20. Bronzoni RVM, Moreli ML, Cruz ACR, Figueiredo LTM. 2004. Multiplex nested PCR
- 574 for Brazilian Alphavirus diagnosis. Trans R Soc Trop Med Hyg 98.
- 575 21. Vina-Rodriguez A, Eiden M, Keller M, Hinrichs W, Groschup MH. 2016. A quantitative
- 576 real-time RT-PCR assay for the detection of venezuelan equine encephalitis virus utilizing
 577 a universal alphavirus control RNA. Biomed Res Int 2016.
- 578 22. Benson DA, Cavanaugh M, Clark K, Karsch-Mizrachi I, Ostell J, Pruitt KD, Sayers EW.
- 579 2018. GenBank. Nucleic Acids Res https://doi.org/10.1093/nar/gkx1094.
- 580 23. Rojas A, Cardozo F, Cantero C, Stittleburg V, López S, Bernal C, Gimenez Acosta FE,
- 581 Mendoza L, Pinsky BA, de Guillén IA, Páez M, Waggoner J. 2019. Characterization of
- dengue cases among patients with an acute illness, Central Department, Paraguay. PeerJ2019.
- 584 24. Claudino-Sales V. 2019. Darien National Park, PanamaCoastal Research Library.
- 585 25. Santiago GA, Vázquez J, Courtney S, Matías KY, Andersen LE, Colón C, Butler AE,
- 586 Roulo R, Bowzard J, Villanueva JM, Muñoz-Jordan JL. 2018. Performance of the
- 587 Trioplex real-time RT-PCR assay for detection of Zika, dengue, and chikungunya viruses.
 588 Nat Commun 9.
- 589 26. Sallum MAM, Forattini OP. 1996. Revision of the spissipes section of culex
- 590 (melanoconion) (diptera: Culicidae). J Am Mosq Control Assoc.
- 591 27. Johnson BW, Kosoy O, Wang E, Delorey M, Russell B, Bowen RA, Weaver SC. 2011.
- 592 Use of Sindbis/eastern equine encephalitis chimeric viruses in plaque reduction

593	neutralization tests for arboviral disease diagnostics. Clinical and Vaccine Immunology
594	18.

- 595 28. Claro IM, Ramundo MS, Coletti TM, da Silva CAM, Valenca IN, Candido DS, Sales
- 596 FCS, Manuli ER, de Jesus JG, de Paula A, Felix AC, Andrade P dos S, Pinho MC, Souza
- 597 WM, Amorim MR, Proenca-Modena JL, Kallas EG, Levi JE, Faria NR, Sabino EC,
- Loman NJ, Quick J. 2021. Rapid viral metagenomics using SMART-9N amplification and
 nanopore sequencing. Wellcome Open Res 6.
- 600 29. Li H. 2018. Minimap2: Pairwise alignment for nucleotide sequences. Bioinformatics 34.
- 601 30. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G,
- Durbin R. 2009. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25.
- 603 31. Oxford Nanopore. 2022. GitHub Create statistic summary of an Oxford Nanopore read604 dataset.
- 605 32. Milne I, Stephen G, Bayer M, Cock PJA, Pritchard L, Cardle L, Shawand PD, Marshall D.
- 606 2013. Using tablet for visual exploration of second-generation sequencing data. Brief607 Bioinform 14.
- Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7:
 Improvements in performance and usability. Mol Biol Evol 30.
- 610 34. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A,
- 611 Lanfear R, Teeling E. 2020. IQ-TREE 2: New Models and Efficient Methods for
- 612 Phylogenetic Inference in the Genomic Era. Mol Biol Evol 37.
- 613 35. Luciani K, Abadía I, Martínez-Torres AO, Cisneros J, Guerra I, García M, Estripeaut D,
- 614 Carrera JP. 2015. Case report: Madariaga virus infection associated with a case of acute
- 615 disseminated encephalomyelitis. American Journal of Tropical Medicine and Hygiene 92.

- 616 36. Torres-ruesta A, Chee RSL, Ng LFP. 2021. Insights into antibody-mediated alphavirus
- 617 immunity and vaccine development landscape. Microorganisms
- 618 https://doi.org/10.3390/microorganisms9050899.
- 619 37. Torres R, Samudio R, Carrera JP, Young J, Maârquez R, Hurtado L, Weaver S, Chaves
- 620 LF, Tesh R, Caâceres L. 2017. Enzootic mosquito vector species at equine encephalitis
- 621 transmission foci in the República de Panama. PLoS One
- 622 https://doi.org/10.1371/journal.pone.0185491.
- 623 38. Carrera J-P, Cucunuba ZM, Neira K, Lambert B, Pitti Y, Liscano J, Garzon JL, Beltran D,
- 624 Collado-Mariscal L, Saenz L, Sosa N, Rodriguez-Guzman LD, Gonzalez P, Lezcano
- 625 AGAG, Pereyra-Elias R, Valderrama A, Weaver SC, Vittor AY, Armien B, Pascale J-M,
- 626 Donnelly CA. 2020. Endemic and epidemic human alphavirus infections in eastern
- 627 Panama: An analysis of population-based cross-sectional surveys. American Journal of
- Tropical Medicine and Hygiene 10:901462.
- 629 39. Dietz WH, Galindo P, Johnson KM. 1980. Eastern equine encephalomyelitis in Panama:
- 630 The epidemiology of the 1973 epizootic. American Journal of Tropical Medicine and
- 631 Hygiene https://doi.org/10.4269/ajtmh.1980.29.133.
- 40. Srihongse S, Galindo P. 1967. The isolation of eastern equine encephalitis virus from
- 633 Culex (Melanoconion) taeniopus Dyar and Knab in Panama. Mosquito News 27:74–76.
- 41. Turell MJ, O'Guinn ML, Jones JW, Sardelis MR, Dohm DJ, Watts DM, Fernandez R,
- 635 Travassos Da Rosa A, Guzman H, Tesh R, Rossi CA, Ludwig G v., Mangiafico JA,
- 636 Kondig J, Wasieloski LP, Pecor J, Zyzak M, Schoeler G, Mores CN, Calampa C, Lee JS,
- 637 Klein TA, 2006. Isolation of Viruses from Mosquitoes (Diptera: Culicidae) Collected in
- 638 the Amazon Basin Region of Peru. J Med Entomol 42:891–898.

	639	42.	Olmo RP, Todiro YMH, Aguiar ERGR, de Almeida JPP, Ferreira F v., Armache JN,	de
--	-----	-----	------------------------------------------------------------------------------	----

- 640 Faria IJS, Ferreira AGA, Amadou SCG, Silva ATS, de Souza KPR, Vilela APP, Babarit
- 641 A, Tan CH, Diallo M, Gaye A, Paupy C, Obame-Nkoghe J, Visser TM, Koenraadt CJM,
- 642 Wongsokarijo MA, Cruz ALC, Prieto MT, Parra MCP, Nogueira ML, Avelino-Silva V,
- 643 Mota RN, Borges MAZ, Drumond BP, Kroon EG, Recker M, Sedda L, Marois E, Imler
- 544 JL, Marques JT. 2023. Mosquito vector competence for dengue is modulated by insect-
- 645 specific viruses. Nat Microbiol 8:135–149.
- 646 43. Relova D, Rios L, Acevedo AM, Coronado L, Perera CL, Pérez LJ. 2018. Impact of RNA
- 647 degradation on viral diagnosis: An understated but essential step for the successful
- 648 establishment of a diagnosis network. Vet Sci 5.

674 Tables

675

676 **Table 1.** Primers and probes in the VEEV and MADV/EEEV rRT-PCRs.

Name	Sequence ^a	Concentration (nM)	Location (5'-3') $^{\circ}$	Sequences Fully Matching ^d
VEEV				
	GAAAGTTCACGTT	200		
VEEV Forward 1	GAYATCGAGGA	200	44.67	15(/150 (09)
VEEV Forward 2	GAAGGTTCACGTT	200	44-67	156/159 (98)
VEEV FORWARd 2	GAYATCGAGGA	200		
VEEV Povorco 1	GCTCTGGCRTTAG	200		
VEEV Reverse 1 VEEV Reverse 2	CATGGTC	200	144-163	159/159 (100)
VEEV Reverse 2	GCTCTAGCRTTAG	200	144-105	139/139 (100)
VEEV Reverse 2 VEEV Probe	CATGGTC	200		
	5'-FAM-			158/159 (99)
VEEV Probe	TTGAGGTAGAAGC	400	112-134	
	HAAGCAGGTC-	+00	112-134	
	BHQ-1-3'			
MADV/EEEV				
ME Forward	GAGATAGAAGCM	400	121-141; 99-119	31/32 (97); 1/449
WIL TO Wald	ACGCAGGTC	+00	121-141, 77-117	(100)
ME Reverse	TGYTTGGAATGCG	400	255-272; 233-250	32/32 (100); 9/449
WIL Reverse	TGTGC	+00	255-272, 255-250	(98)
	5'-FAM-			31/32 (97)
MADV Probe	CATCGAAAGCGAA	200	195-214	
MADV Probe	GTGGACC-BHQ-1-	200	175-214	
	3'			
	5'-CFO560-			6/449 (99)
EEEV Probe	TGAGGGAGAAGT	400	176-198	
	GGAYACAGACC-			

BHQ-1-3'

Abbreviations: BHQ, black hole quencher; CFO560, CAL Fluor Orange 560; FAM,	Fluorescein

- ^a probe sequences listed 5'-fluorophore-sequence-quencher-3'
- 681 ^b Concentration in the final reaction mixture

- ^c Location in the following complete genome sequences: VEEV strain VEEV/Homo sapiens/GTM/69Z1/1969/IAB
- 683 (Accession number KC344505.2); MADV strain Homo sapiens/Haiti-1901/2016 (MH359233.1); EEEV strain
- 684 EEEV/Culiseta melanura/USA/SL13-0764-C/2013 (Accession number KX029319.1)
- ^d Displayed as number of complete genome sequences without a mismatch in the primer/probe sequence over all
- 686 complete genome sequences aligned (%). Genomes downloaded 22 Sept 2021. Data shown for the combination of
- 687 forward and reverse VEEV primers.

Table 2. Characteristics and laboratory results of samples used for protocol validation patients and clinical samples and

laboratory results. Acute samples selected from the 2015 and 2017 alphavirus outbreaks in Darien Province.

Code	Townshi p	Age *	Se x	Sympto ms onset	Days of sympto ms	RT-PCR- Alpha (2015)	RT-PCR- Alpha (2021)	rRT-PCR- VEE	Ct values	IgM- VEEV	IgM- MADV	IgG- VEEV	IgG- MADV	PRNT- VEEV φ	PRNT- MADV φ
25838 4	El Real	0-9	М	Aug. 2015	0	pos	neg	pos	29.3	neg	neg	neg	neg	<1:20	<1:20
26773 8	Cemaco	0-9	М	July 2017	3	neg	neg	pos	37.8	pos	neg	neg	neg	<1:20	<1:20
26741 1	Tucuti	0-9	F	July 2017	5	neg	neg	neg	-	pos	neg	pos	pos	1:40	1:40
25838 0	El Real	0-9	F	Aug. 2015	1	pos	neg	neg	-	neg	neg	neg	neg	<1:20	<1:20
26741 0	Yaviza	0-9	F	July 2017	2	neg	neg	neg	-	pos	neg	pos	neg	<1:20	<1:20
25865 7	Yaviza	10- 19	М	Sept. 2015	0	pos	neg	pos	28	neg	neg	neg	neg	<1:20	<1:20
25853 5	Nicanor	20- 29	F	Sept. 2015	2	pos	neg	neg	-	neg	neg	neg	neg	<1:20	<1:20
25840 1	La Palma	20- 29	М	Aug. 2015	2	pos	neg	pos	29	neg	neg	neg	neg	<1:20	<1:20
25839 5	Metetí	30- 39	М	Aug. 2015	2	neg	neg	pos	37	pos	neg	neg	neg	<1:20	<1:20
25839 9	El Real	30- 39	М	Aug. 2015	1	pos	neg	pos	26	neg	neg	neg	neg	<1:20	<1:20
25838 5	El Real	30- 39	М	Aug. 2015	2	pos	neg	pos	37	neg	neg	neg	neg	<1:20	<1:20
25839 8	El Real	30- 39	М	Aug. 2015	0	pos	neg	pos	27	neg	neg	pos	neg	<1:20	<1:20
25853 6	Metetí	30- 39	F	Sept. 2015	2	pos	neg	neg	-	neg	neg	neg	neg	<1:20	<1:20
25838 6	El Real	30- 39	М	Aug. 2015	5	pos	neg	pos	34	neg	neg	neg	neg	ND	ND
25837 9	El Real	≥ 40	F	Aug. 2015	2	pos	neg	pos	31	neg	neg	neg	neg	<1:20	<1:20

*Age categories in year s

ϕ Base on PRNT-80 Abbreviations: Ct, cycle threshold; neg, negative; pos, positive, ND=not done.

Table 3. Mosquito species collected during the 2015 outbreak in El Real de Santa Maria,

Panama.

Mosquitos	Ν	(%)	# Pools	VEE-rRT-	MADV-rRT-	
species				PCR	PCR	Viral
				Positive	Positive	solates
Coquillettidia venezuelensis	490	37.5	29	0	0	0
Culex	450	34.4	27	3	0	2
(Melanoconion) vomerifer						
Culex	32	2.4	4	0	0	0
(Melanoconion) pedroi						
Aedes serratus	31	2.4	7	0	0	0
Aedes sp.	30	2.3	5	0	0	0
Culex	30	2.3	6	0	0	0
(Melanoconion) sp.						
Culex (Culex) interrogator	27	2.1	5	0	0	0
Anopheles trianulatus	23	1.8	2	0	0	0
Aedes eupoclamus	14	1.1	4	0	0	0
Culex (Culex) nigripalpus	14	1.1	3	0	0	0
Culex (Culex)	14	1.0	4	0	0	0
sp. Culex	14	1.0	1	0	0	0
(Melanoconion) atratus						
Culex	13	1.0	3	0	0	0
(Melanoconion) adamesi						
Others*	125	9.6	50	0	0	0
Total	1307	100	150	3	0	2

Species <1% abundance are listed as Others.

Numbers of mosquito pools

Table 4. Metadata and sequencing statistics for selected VEEV complex RNA positive

samples.

ID	Collection date	Location	Host species	%genome coverage 20X	% Nt Identity with genome referencea	% Identity with strain 3880b
700677	2015	Darien	Culex (Mel.) vomerifer	100	89.8	92.1
700680	2015	Darien	Culex (Mel.) vomerifer	100	89.8	92.2
700732	2015	Darien	Culex (Mel.) vomerifer	100	90	92.3
258379	2015	Darien	Human	99.9	89.6	92
258398	2015	Darien	Human	70	88.7	90.7
258401	2015	Darien	Human	90.6	87.7	90
278716	2022	Darien	Human	45.98	88.1	90

^aGenbank accession no. NC_001449.1

^bPanamanian VEEV ID subtype prototype strain 3880, GenBank accession no. L00930.1 Nt=Nucleotide.

Figure legends

Figure 1. Map with the distribution of VEEV human cases in Darien province in 2015 and

2017 and Health centres in Panama and Darien Provinces. A. Distribution of VEEV cases

used for protocol validation. Red dots represent the number of cases reported by locality. B.

Distribution of Health centers used for prospective febrile surveillance in Panama and Darien

provinces. Map was created with ArcGIS Desktop 10.6 using shapefiles from Esri. Data sources

for the shapefiles include Esri, Garmin International Inc., US Central Intelligence Agency, and

National Geographic Society (39).

Figure 2. VEE and MADV/EEEV rRT-PCR linearity and limit of detection. A)

Amplification curves across the linear range of the VEE complex rRT-PCR with ssDNA (gray curves, subtype IAB) and RNA (pink dotted curves, subtype IC). **B**) Linearity and limit of detection for VEE were evaluated with ssDNA from subtypes IAB (grey) and IV (purple) and RNA from subtype IC (pink). (**C-D**) Linearity and limit of detection for MADV \bigcirc and EEEV (D) were evaluated using ssDNA. For each virus, ssDNA was tested in quadruplicate at 8.0, 6.0, 4.0, 2.0 and 1.0 log₁₀ copies/µL (labelled a-e, respectively). 10-fold dilutions of VEEV subtype IC RNA were tested in duplicate starting at the highest concentration available (5.0 log₁₀ copies/µL). All data points are displayed, including 2/4 MADV and EEEV replicates that did not yield cycle threshold (Ct) values and were excluded from the linear regressions.

Figure 3. Flowchart of patient recruitment, characteristics and RT-PCR results of febrile patients detected throughout disease surveillance. Febrile patients were recruited from November 16, 2021, to December 1, 2022, in ten health care centers of Panama and Darien provinces.

Figure 4. VEEV complex maximum likelihood phylogenetic tree. Maximum likelihood phylogenic was estimated using 139 complete or near complete VEEV genomes. Publicly available Panamanian VEEV ID subtype strains are highlighted in grey (n=) and genomes generated in this study (n=7) are highlighted in red. Bootstrap statistical support are shown for selected nodes. NCBI GenBank accessions numbers for the new VEEV genomes are: XX-XX.




Figure 1. Map with the distribution of VEEV human cases in Darien province in 2015 and 2017 and Health centres in Panama and Darien Provinces.

Figure 2. VEE and MADV/EEEV rRT-PCR linearity and limit of detection.





Figure 3. Flowchart of patient recruitment, characteristics and RT-PCR results of

febrile patients detected throughout disease surveillance.





1981.AB66640_VEEVIAB_.Venezuela 1938.BeckWycoff.Venezuela **−**⁰ 1977.R16905.Ecuador 1967.COAN5506.Australia 1967.CoAn5384.Colombia 1969.69Z1.Guatemala - 1973.E541_73.Venezuela 1969.E123_69.Venezuela 1968.E1_68.Venezuela 1962.PHO127.Venezuela 1973.204381.Venezuela - 1997.ZPC727.Venezuela └── 1999.993MM3041.Colombia -0 2000.00SMH279.Colombia • 1997.97CO42.Colombia 2000.00SMM49512.Colombia 2001.CO970054.Colombia 2000.00SMM48011.Colombia 2000.00SMH264.Colombia -0 2003.213391.Panama -• 2015.258401.Panama 2015.258398.Panama • 2015.258379.Panama • 2015.700680.Panama 2015.700677.Panama 2022.278716.Panama • 2015.700732.Panama 2001.485029.Panama 2003.212857.Panama 2001.484551.Panama -0 2000.481460.Panama 1977.903104.Panama 1997.474590.Panama -0 1984.GML903843.Panama 1995.IQT1724.Peru 1998.02272098.Peru 1994.IQT1098.Peru -0 2013.CFI2256.Peru - 1997.IQT3971.Peru - 1997.MAC10.Venezuela - 2013.EVG395.Australia

Panama/Peru **VEEV ID** Subtype

- 1969.CoAn9004.Colombia